Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
暂无分享,去创建一个
S. Hanauer | P. Rutgeerts | W. Sandborn | R. Panaccione | J. Panés | R. Fedorak | P. Rutgeerts | M. Lukáš | D. Macintosh | D. Wolf | J. Kent | B. Bittle | J. Li | P. Pollack | Ju Li | J. Li | R. Fedorak | Subrata Ghosh | D. Wolf | Stephen B. Hanauer | Richard N. Fedorak | William Sandborn | Milan Lukas | Jeffrey D. Kent | Barry Bittle | William J. Sandborn | Julián Panés | Subrata Ghosh | S. Hanauer | P. Rutgeerts | R. Fedorak | D. Wolf | J. D. Kent | Jacky Yu-Chung Li | Jeffrey D. Kent
[1] P. Rutgeerts,et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.
[2] P. Rutgeerts,et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.
[3] G. Radford-Smith,et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial , 2004, Gut.
[4] M. Bala,et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[5] E. Keystone,et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.
[6] P. van Riel,et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate , 2004, Scandinavian journal of rheumatology.
[7] M. Dougados,et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed , 2004, Annals of the rheumatic diseases.
[8] P. Rutgeerts,et al. Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.
[9] G. Radford-Smith,et al. CDP 571 , a humanised monoclonal antibody to tumour necrosis factor a , for moderate to severe Crohn ’ s disease : a randomised , double blind , placebo controlled trial , 2004 .
[10] V. Strand,et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). , 2003, The Journal of rheumatology.
[11] P. Emery,et al. Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study , 2003, Annals of the rheumatic diseases.
[12] H. Paulus,et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. , 2003, Clinical therapeutics.
[13] S. Plevy,et al. The Incidence and Management of Infusion Reactions to Infliximab: A Large Center Experience , 2003, American Journal of Gastroenterology.
[14] M. Peppercorn,et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. , 2003, Gastroenterology.
[15] An Carbonez,et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.
[16] M. Weisman,et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.
[17] L. V. D. van de Putte,et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. , 2002, The Journal of rheumatology.
[18] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[19] S. Targan,et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. , 2001, Gastroenterology.
[20] S. Targan,et al. Tumor necrosis factor: biology and therapeutic inhibitors. , 2000, Gastroenterology.
[21] S. Romagnani. Th1/Th2 cells. , 1999, Inflammatory bowel diseases.
[22] E. Vasiliauskas,et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.
[23] P. Rutgeerts,et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.
[24] Van Deventer,et al. Tumour necrosis factor and Crohn's disease. , 1997 .
[25] S. Targan,et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.
[26] J. Rochon,et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. , 1994, Gastroenterology.
[27] T. Macdonald,et al. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. , 1993, Gut.
[28] S. Stephens,et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation , 1992, The Lancet.
[29] M. Savage,et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. , 1991, Gut.
[30] F Kern,et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.